Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
CEACAM5mRNA
CellSearch system
circulating tumors cells
first-line chemotherapy
liquid biopsy
monitoring
non-small cell lung cancer
predictive biomarkers
prognostic biomarkers
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Jan 2021
18 Jan 2021
Historique:
received:
08
12
2020
revised:
13
01
2021
accepted:
14
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
8
9
2021
Statut:
epublish
Résumé
We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time points during first-line chemotherapy. CellSearch revealed the detection of ≥1 CTCs in 41.9%, 40.9%, and 16.7% of patients at baseline, post-1st, and post-2nd treatment cycle, respectively, and of ≥5 CTCs in 11.6%, 9.1%, and 5.6%, respectively. CEACAM5mRNA+ CTCs were detected in 29.3% and 16% of patients pre- and post-treatment, respectively. The positivity concordance between the two assays was 2.2%. CTC-detection by CellSearch (≥5 CTCs:
Identifiants
pubmed: 33477700
pii: ijms22020925
doi: 10.3390/ijms22020925
pmc: PMC7831933
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
CEACAM5 protein, human
0
Carcinoembryonic Antigen
0
GPI-Linked Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hellenic Society of Medical Oncology
ID : HESMO
Organisme : Anticancer Research Support Association
ID : ARSA
Organisme : Cretan Association for Biomedical Research
ID : CABR
Références
Cancer Chemother Pharmacol. 2018 Nov;82(5):767-775
pubmed: 30094617
Genet Mol Res. 2015 Sep 01;14(3):10352-8
pubmed: 26345975
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
Sci Rep. 2019 Aug 12;9(1):11680
pubmed: 31406218
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Sci Rep. 2016 Jun 15;6:28010
pubmed: 27302574
Cancers (Basel). 2020 Jun 12;12(6):
pubmed: 32545559
Respirology. 2016 Apr;21(3):519-25
pubmed: 26661896
Br J Cancer. 2012 Jun 5;106(12):1917-25
pubmed: 22669159
Clin Cancer Res. 2016 May 1;22(9):2197-206
pubmed: 26667488
Breast Cancer Res. 2018 Jun 8;20(1):48
pubmed: 29884204
Oncol Res. 2012;20(2-3):131-7
pubmed: 23193919
Clin Cancer Res. 2012 Apr 15;18(8):2391-401
pubmed: 22492982
Cancers (Basel). 2014 Jan 21;6(1):153-65
pubmed: 24452143
Int J Cancer. 2011 Oct 1;129(7):1651-60
pubmed: 21128227
Clin Cancer Res. 1998 Sep;4(9):2141-6
pubmed: 9748132
J Clin Oncol. 1997 Nov;15(11):3388-93
pubmed: 9363870
PLoS One. 2013 Nov 04;8(11):e78070
pubmed: 24223761
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
J Thorac Oncol. 2012 Feb;7(2):306-15
pubmed: 22173704
Mol Med Rep. 2017 Jul;16(1):625-630
pubmed: 28586008
Mol Cancer Ther. 2019 Feb;18(2):437-447
pubmed: 30401696
Oncogene. 2002 Nov 7;21(51):7817-23
pubmed: 12420218
J Natl Cancer Inst. 2014 May 15;106(5):
pubmed: 24832787
J Transl Med. 2019 Mar 8;17(1):74
pubmed: 30849967
J Clin Oncol. 2011 Apr 20;29(12):1556-63
pubmed: 21422424
Cancers (Basel). 2020 Feb 06;12(2):
pubmed: 32041353
Br J Cancer. 2011 Sep 6;105(6):847-53
pubmed: 21829190
Br J Cancer. 1998 Nov;78(10):1368-72
pubmed: 9823981
Clin Cancer Res. 2011 Jan 1;17(1):165-73
pubmed: 21071514
Cancer Biomark. 2014;14(4):215-23
pubmed: 24934364
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2017 Apr 18;8(16):26112-26121
pubmed: 28212540
Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108
pubmed: 28523597
Oncology. 2006;70(3):203-11
pubmed: 16809939
J Thorac Dis. 2017 Oct;9(Suppl 13):S1332-S1345
pubmed: 29184672